Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Inks Group Purchasing Agreement With Premier

NEW YORK (GenomeWeb) — NeoGenomics announced today that it has signed a group purchasing agreement for its clinical reference laboratory testing services with healthcare provider network Premier.

Under the terms of the deal, Premier members — which include roughly 4,000 hospitals and 165,000 other providers throughout the US — can access NeoGenomics services at special pre-negotiated prices and terms. Additional terms were not disclosed.

Included in the arrangement are NeoGenomics' bone marrow and surgical pathology consults; cancer cytogenetics; hematologic and solid tumor FISH testing; and more than 150 molecular oncology tests.

"The agreement underscores NeoGenomics' unique position as a national, oncology-focused laboratory," NeoGenomics Chairman and CEO Douglas VanOort said in a statement. "We look forward to providing a comprehensive suite of cancer tests, along with our tradition of outstanding customer service, to Premier members across the country."

NeoGenomics — which recently reported a 9 percent increase in Q2 revenues amid improved performance of its clinical services division — signed a similar purchasing agreement with Premier in 2015.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.